Glucocorticoids in the treatment of severe sepsis and septic shock

被引:55
作者
Annane, D [1 ]
机构
[1] Univ Versailles, Serv Reanimat Med, Hop Raymond Poincare, APHP,Fac Med Paris Ouest, F-92380 Garches, France
关键词
adrenal cortex hormones; animal studies; clinical pharmacology; clinical trials; sepsis;
D O I
10.1097/01.ccx.0000176691.95562.43
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Purpose of review Septic shock remains runs of the leading causes of death in intensive care units. In recent years, there is general use of low to moderate doses of corticosteroids in the treatment of septic shack. However; there are wide variations in the practical modality of this treatment, mainly with regard to patients' selection, treatment's dose, timing, route of administration, duration, and weaning. This review provides opinion-based guidelines for the use of corticosteroids in severe sepsis and septic shock. Recent findings A summary of the latest understanding of the mechanisms of action of corticosteroids and the most recent observations in the clinical and biologic responses to corticosteroids in severe sepsis and septic shock is presented. Summary In septic shock, intravenous hydrocortisone should be started immediately after a 250 mu g corticotropin test, at a dose of 200-300 mg per day. When adrenal insufficiency is confirmed, treatment should be continued at full doses for 7 days. Otherwise, hydrocortisone should be stopped. It is worth considering adding enteral fludrocortisone at a dose of 50 mu g per day for 7 days. In severe sepsis, despite growing evidence to support the use of a moderate dose of corticosteroids, the efficacy and safety of this treatment needs to be assessed in a large-scale study.
引用
收藏
页码:449 / 453
页数:5
相关论文
共 50 条
  • [1] Septic shock
    Annane, D
    Bellissant, E
    Cavaillon, JM
    [J]. LANCET, 2005, 365 (9453) : 63 - 78
  • [2] Annane D, 1998, BRIT J CLIN PHARMACO, V46, P589
  • [3] Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis
    Annane, D
    Bellissant, E
    Bollaert, PE
    Briegel, J
    Keh, D
    Kupfer, Y
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7464): : 480 - 484
  • [4] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [5] Annane D, 2003, NEW ENGL J MED, V348, P2157
  • [6] ANNANE D, 2005, IN PRESS CRIT CARE M
  • [7] IMMUNOSUPPRESSION BY GLUCOCORTICOIDS - INHIBITION OF NF-KAPPA-B ACTIVITY THROUGH INDUCTION OF I-KAPPA-B SYNTHESIS
    AUPHAN, N
    DIDONATO, JA
    ROSETTE, C
    HELMBERG, A
    KARIN, M
    [J]. SCIENCE, 1995, 270 (5234) : 286 - 290
  • [8] CORTICOSTEROIDS SUPPRESS CYCLOOXYGENASE MESSENGER-RNA LEVELS AND PROSTANOID SYNTHESIS IN CULTURED VASCULAR CELLS
    BAILEY, JM
    MAKHEJA, AN
    PASH, J
    VERMA, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 157 (03) : 1159 - 1163
  • [9] GLUCOCORTICOID RECEPTOR-BETA, A POTENTIAL ENDOGENOUS INHIBITOR OF GLUCOCORTICOID ACTION IN HUMANS
    BAMBERGER, CM
    BAMBERGER, AM
    DECASTRO, M
    CHROUSOS, GP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) : 2435 - 2441
  • [10] INFLUENCE OF HYPERCORTISOLEMIA ON SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR-II AND INTERLEUKIN-1 RECEPTOR ANTAGONIST RESPONSES TO ENDOTOXIN IN HUMAN-BEINGS
    BARBER, AE
    COYLE, SM
    FISCHER, E
    SMITH, C
    VANDERPOLL, T
    SHIRES, T
    LOWRY, SF
    [J]. SURGERY, 1995, 118 (02) : 406 - 411